Purple Biotech Ltd ADR (PPBT)

$2.12 -0.13 (-5.78%)
Market Cap 5.82M
Revenue (ttm) 0.00
Net Income (ttm) -7.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 103,600
Avg Vol 119,260
Day's Range N/A - N/A
Shares Out 2.59M
Stochastic %K 2%
Beta 0.41
Analysts Strong Sell
Price Target $34.00

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 933 3121
Fax: 972 3 509 7196
Address:
4 Oppenheimer Street, Science Park, Rehovot, Israel
Wkdwalker
Wkdwalker Jul. 30 at 9:23 AM
$PPBT all my shares have been returned, double bottom. Thursday tomorrow… maybe news day?
0 · Reply
KcKc88
KcKc88 Jul. 30 at 3:55 AM
$PPBT idk.. I mean can they safely drop below 6M market cap?
1 · Reply
hylandcow
hylandcow Jul. 30 at 1:09 AM
$PPBT doesn't he say that before every missed data point and then reverse split
0 · Reply
Joebama69
Joebama69 Jul. 30 at 12:52 AM
$PPBT shorting this scan stock is putting my kids through college.
1 · Reply
StocHolliday
StocHolliday Jul. 29 at 11:29 PM
$PPBT did Hamas blow up our headquarters or what happened?
2 · Reply
Smittysixty
Smittysixty Jul. 29 at 9:59 PM
$PPBT Why does it suddenly feel like there’s urgency to cover or accumulate? 🧐 Who’s going to show up in the updated 13Fs by August 15th? Is there brewing news around CM24 partnership or trial funding? I still believe NT-219’s full data lands at ESMO—but that’s not until late September. So what’s behind the recent and erratic price action and surge in troll noise? Feels like something else is stirring before then. Volume whispers louder than any words posted on this page.
0 · Reply
LarryHParker
LarryHParker Jul. 29 at 9:45 PM
$PPBT I’m just glad I didn’t convince friends and family to invest 🤣. I’ll take this one on the chin but I would have fumbled some close relationships
0 · Reply
GetMePaid41
GetMePaid41 Jul. 29 at 9:24 PM
$PPBT 5k turned into $270 in 5 years. Israeli scam, enriching themselves. Sounds about right
1 · Reply
Purplepayday
Purplepayday Jul. 29 at 8:08 PM
$PPBT Yami can get ready to do some more buy’s soon 👍
0 · Reply
Stocksavior14
Stocksavior14 Jul. 29 at 8:00 PM
$PPBT that would be mega bullish for the permabulls
0 · Reply
Latest News on PPBT
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jul 23, 2025, 7:00 AM EDT - 7 days ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Jun 23, 2025, 7:00 AM EDT - 5 weeks ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025, 7:10 AM EDT - 2 months ago

Purple Biotech Reports First Quarter 2025 Financial Results

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025, 7:30 AM EDT - 2 months ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Apr 28, 2025, 8:28 AM EDT - 3 months ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 10, 2025, 8:57 AM EDT - 5 months ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Feb 18, 2025, 7:00 AM EST - 5 months ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 5, 2024, 7:13 AM EST - 8 months ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 8 months ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Why Is Purple Biotech Stock Trading Higher On Monday?

Dec 2, 2024, 9:18 AM EST - 8 months ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 7:00 AM EST - 9 months ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Nov 4, 2024, 7:50 AM EST - 9 months ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 25, 2024, 7:20 AM EDT - 9 months ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 10 months ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Sep 18, 2024, 6:30 AM EDT - 11 months ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 30, 2024, 7:00 AM EDT - 11 months ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 16, 2024, 8:12 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 25, 2024, 7:35 AM EDT - 1 year ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 2, 2024, 4:00 PM EDT - 1 year ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 1 year ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 27, 2024, 7:45 AM EDT - 1 year ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Jun 1, 2024, 8:00 AM EDT - 1 year ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Purple Biotech Reports First Quarter 2024 Financial Results

May 21, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2024 Financial Results

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 14, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 5, 2024, 7:55 AM EST - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 27, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 13, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Feb 1, 2024, 7:30 AM EST - 1 year ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 20, 2023, 8:05 AM EST - 1 year ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Dec 14, 2023, 6:50 AM EST - 1 year ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Purple Biotech Reports Third Quarter 2023 Financial Results

Nov 21, 2023, 6:50 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 19, 2023, 3:55 PM EDT - 1 year ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 1 year ago

Purple Biotech Announces $5 Million Registered Direct Offering

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 6, 2023, 7:50 AM EDT - 1 year ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Oct 3, 2023, 7:50 AM EDT - 1 year ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Purple Biotech Reports Second Quarter 2023 Financial Results

Aug 22, 2023, 9:29 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Jul 11, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

May 16, 2023, 4:00 PM EDT - 2 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 19, 2023, 8:15 AM EDT - 2 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Apr 18, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Mar 24, 2023, 7:00 AM EDT - 2 years ago

Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

Feb 14, 2023, 7:01 AM EST - 2 years ago

Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial

Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

Feb 8, 2023, 7:12 AM EST - 2 years ago

Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis

Nov 15, 2022, 7:00 AM EST - 2 years ago

Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis

Purple Biotech Reports Third Quarter 2022 Financial Results

Nov 8, 2022, 7:53 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2022 Financial Results

Purple Biotech Appoints Lior Fhima as Chief Financial Officer

Nov 2, 2022, 7:37 AM EDT - 2 years ago

Purple Biotech Appoints Lior Fhima as Chief Financial Officer

Purple Biotech Reports Second Quarter 2022 Financial Results

Aug 4, 2022, 7:30 AM EDT - 3 years ago

Purple Biotech Reports Second Quarter 2022 Financial Results

Purple Biotech Announces Executive Leadership Changes

Jul 14, 2022, 7:30 AM EDT - 3 years ago

Purple Biotech Announces Executive Leadership Changes

Wkdwalker
Wkdwalker Jul. 30 at 9:23 AM
$PPBT all my shares have been returned, double bottom. Thursday tomorrow… maybe news day?
0 · Reply
KcKc88
KcKc88 Jul. 30 at 3:55 AM
$PPBT idk.. I mean can they safely drop below 6M market cap?
1 · Reply
hylandcow
hylandcow Jul. 30 at 1:09 AM
$PPBT doesn't he say that before every missed data point and then reverse split
0 · Reply
Joebama69
Joebama69 Jul. 30 at 12:52 AM
$PPBT shorting this scan stock is putting my kids through college.
1 · Reply
StocHolliday
StocHolliday Jul. 29 at 11:29 PM
$PPBT did Hamas blow up our headquarters or what happened?
2 · Reply
Smittysixty
Smittysixty Jul. 29 at 9:59 PM
$PPBT Why does it suddenly feel like there’s urgency to cover or accumulate? 🧐 Who’s going to show up in the updated 13Fs by August 15th? Is there brewing news around CM24 partnership or trial funding? I still believe NT-219’s full data lands at ESMO—but that’s not until late September. So what’s behind the recent and erratic price action and surge in troll noise? Feels like something else is stirring before then. Volume whispers louder than any words posted on this page.
0 · Reply
LarryHParker
LarryHParker Jul. 29 at 9:45 PM
$PPBT I’m just glad I didn’t convince friends and family to invest 🤣. I’ll take this one on the chin but I would have fumbled some close relationships
0 · Reply
GetMePaid41
GetMePaid41 Jul. 29 at 9:24 PM
$PPBT 5k turned into $270 in 5 years. Israeli scam, enriching themselves. Sounds about right
1 · Reply
Purplepayday
Purplepayday Jul. 29 at 8:08 PM
$PPBT Yami can get ready to do some more buy’s soon 👍
0 · Reply
Stocksavior14
Stocksavior14 Jul. 29 at 8:00 PM
$PPBT that would be mega bullish for the permabulls
0 · Reply
Stocksavior14
Stocksavior14 Jul. 29 at 7:59 PM
$PPBT it’s coming, from dilution. Little by little or school is putting some up.
0 · Reply
Purplepayday
Purplepayday Jul. 29 at 7:53 PM
$PPBT If it close under $2.13 … Then it looks very bad 🧐🫣
0 · Reply
SirGay_LoveRaw
SirGay_LoveRaw Jul. 29 at 7:45 PM
$PPBT I truly hope none of you guys advertised this "small Israeli biotech with game changing drugs and 10x potential" to family and friends four years ago. ...but if you did, do tell the story if it's not too sad! :D
1 · Reply
PPBTPhoenix
PPBTPhoenix Jul. 29 at 7:20 PM
$PPBT seems like a simple enough question
1 · Reply
Purplepayday
Purplepayday Jul. 29 at 7:06 PM
$PPBT Are you still buying more shares here after 4-5 years of downtrend ? Here is why you still do that ! https://asana.com/resources/sunk-cost-fallacy
0 · Reply
Mattblock
Mattblock Jul. 29 at 6:58 PM
$PPBT let’s just take one of Gil’s upcoming catalyst from his letter to the shareholders: Plan to advance CM24 into a biomarker-driven Phase 2b study in second-line PDAC targeting approximately 165 patients. This would cost ~20-25 million dollars. Money has to be coming or this is a lie
2 · Reply
sacalino
sacalino Jul. 29 at 6:43 PM
$PPBT 79 days to the doors of Hell. Massing nothing burger as always or good news tanks the stock. Been there, seen that
0 · Reply
GoGetYourShineBox
GoGetYourShineBox Jul. 29 at 6:30 PM
$PPBT We’ll I’m ready for a Cup of coffee… in the big time… time for a change!
0 · Reply
Smittysixty
Smittysixty Jul. 29 at 5:49 PM
$PPBT Funny how trolls go silent when you bring up actual science. They scramble to change the subject—anything to avoid the clinical facts and real potential these drugs have for cancer patients. All they’ve got is “the science hasn’t helped the share price”—same recycled line used against every small-cap biotech before it was acquired. They want you to believe science doesn’t matter. But Izzy was right: good data always wins. And when NT-219’s full dataset drops, we win. ESMO’s closing in. Stay sharp. Ignore the noise.
0 · Reply
Purplepayday
Purplepayday Jul. 29 at 5:47 PM
$PPBT But… The fact right now is that the pipeline doesn’t matter it seems like…..
0 · Reply
Smittysixty
Smittysixty Jul. 29 at 5:45 PM
$PPBT $6M market cap. $70B+ conservative addressable market estimate across oncology: 🧪 CM24: Anti-CEACAM1 mAb for pancreatic, gastric, biliary & CEACAM1+ tumors (~$18–20B potential) 🧬 NT-219: STAT3 + IRS1/2 dual inhibitor for SCCHN, PD-1 resistant & KRAS+ tumors (~$20–25B potential) ⚔️ CAPTN-3: Tri-specific antibody platform for 5T4+ tumors, modular expansion to EGFR/NKG2D (~$25–35B potential) Multi-modal assault on resistance, immune evasion & biomarker-driven precision. Now focus turns to ESMO—data catalysts inbound..
0 · Reply
Smittysixty
Smittysixty Jul. 29 at 5:40 PM
$PPBT Let’s talk facts—not fear. The pipeline is stacked. 🧪 CM24 — Phase 2 in pancreatic cancer showed 79% reduction in risk of death in biomarker-enriched patients A — ORR hit 50% vs 0% in control group A — PFS improved by 2.9 months, OS by 5.1 months A — Phase 2b biomarker-driven study planned across multiple indications B 🧬 NT-219 — Completed Phase 1/2 trial May 8, 2024 — Demonstrated activity in head & neck cancer with cetuximab combo B — Phase 2 underway with University of Colorado Anschutz, including combo with Keytruda B — Targets resistance pathways in KRAS-driven tumors and enhances PD-1 efficacy C ⚔️ CAPTN-3 — Engages T cells + NK cells with masked CD3, NKG2A, and tumor antigen arms D — Presented at EACR 2025 and ASGCT 2025 for its checkpoint-blocking, resistance-busting design D 📈 Pipeline validated by academic partnerships, biomarker-driven strategy, and clinical wins. Trolls cry fear. The data screams value.
0 · Reply